sponsored
PatientsVille.com Logo

PatientsVille

Sandostatin Lar Sas02 vial Medical Research Studies

Up-to-date List of Sandostatin Lar Sas02 vial Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Sandostatin Lar Sas02 vial Medical Research Studies

Rank Status Study
1 Recruiting A Comparison of MRI Perfusion and FDG PET/CT to Distinguish Between Radiation Injury and Tumor Progression
Condition: Brain Cancer
Intervention: Other: MRI perfusion and PET/CT scans
Outcome Measures: imaging techniques;   predicting tumor progression
2 Recruiting Exploring Biological Linkage Between Circadian Disruption and Cancer Progression
Condition: Breast Neoplasms
Intervention:
Outcome Measures: Progression-free survival;   Circadian disruption;   Objective sleep cycle measures;   Physiological measures;   Sleep quality measures;   Quality of Life measure;   Cancer related Fatigue;   Distress related measure;   Posttraumatic Stress-related symptom measure;   Menopausal symptom measure;   Personality measure;   Genetic polymorphism;   Epigenetic Change;   Cortisol level;   Melatonin;   Inflammatory markers;   Overall survival
3 Unknown  Studying Biomarkers in Samples From Younger Patients With Malignant Germ Cell Tumor Progression
Conditions: Childhood Germ Cell Tumor;   Extragonadal Germ Cell Tumor;   Ovarian Cancer;   Testicular Germ Cell Tumor
Interventions: Genetic: DNA methylation analysis;   Genetic: mutation analysis;   Genetic: nucleic acid sequencing;   Genetic: polymerase chain reaction;   Genetic: polymorphism analysis;   Other: laboratory biomarker analysis;   Other: medical chart review
Outcome Measures: Event-free survival;   Genomic prognostic signatures associated with GCTS;   Genetic variants that contribute to GCTS pathogenesis
4 Recruiting Third-line Treatment of Gefitinib in NSCLC Patients
Condition: Non Small Cell Lung Cancer
Intervention: Drug: Gefitinib
Outcome Measures: Disease Control Rate (DCR);   objective response rate (ORR), progressive-free survival (PFS), overall survival(OS)
5 Unknown  The Impact of M1/M2 Tumor Associated Macrophage (TAM) Polarization on Cancer Progression and Prognosis Prediction
Conditions: Tumor;   Lung Cancer
Intervention:
Outcome Measures: outcome (treatment response and mortality);   clinical presentation
6 Unknown  Selenium and Vitamin E in Preventing Cancer Progression and Recurrence in Patients With Early-Stage Bladder Cancer
Condition: Bladder Cancer
Interventions: Drug: selenium;   Drug: vitamin E;   Procedure: chemoprevention
Outcome Measures: Recurrence-free interval;   Overall survival time;   Incidence of transitional cell carcinoma outside the bladder;   Incidence of all other malignancies clinically diagnosed;   Incidence of cardiovascular events;   Quality of life as assessed at each follow-up visit by the quality of life instruments EORTC QLQ-C30, QLQ-BLS24 and QLQ-BLM30;   Progression-free interval
7 Recruiting The Natural History of Small Renal Masses
Condition: Patients With Newly Diagnosed Small Renal Masses(<4cm)
Intervention:
Outcome Measures: Tumour progression:;   Time to Tumour Progression;   Growth rate
8 Recruiting A Study of Avastin (Bevacizumab) in Combination With Temolozomide (TMZ) and Radiotherapy in Paediatric and Adolescent Patients With High-Grade Glioma
Condition: Glioma
Interventions: Drug: bevacizumab [Avastin];   Radiation: Radiotherapy;   Drug: temozolomide (TMZ)
Outcome Measures: Event-free survival defined as the earliest occurrence of any one of the following: tumor progression, tumor recurrence, second primary non-high grade (HGG) malignancy or death attributable to any cause as determined by the local investigator;   Overall survival;   1-year overall survival;   6-months event free survival defined as the earliest occurrence of any one of the following: tumor progression, tumor recurrence, second primary non-high grade (HGG) malignancy or death attributable to any cause;   1-year EFS. Event-free survival defined as the earliest occurrence of any one of the following: tumor progression, tumor recurrence, second primary non-high grade (HGG) malignancy or death attributable to any cause;   Safety: Incidence of adverse events;   Overall response rate (ORR) as determined by the Central Radiology Review Committee based on Response Assessment in Neuro-Oncology (RANO) criteria;   Functional changes in tumor assessed by magnetic resonance imaging (MRI);   Health status as measured by the Health Utility Index (HUI) between the treatment arms (for patients aged 5 years and older);   Neurological psychological function as measured by the Wechsler scale between the treatment arms
9 Recruiting A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
Conditions: Breast Cancer;   Neoplasm Metastasis
Interventions: Other: Standard supportive care (packed RBC transfusion);   Drug: epoetin alfa + packed RBC transfusion
Outcome Measures: Progression free survival, measured in months from the date of randomization to the date of the first documented disease progression or death, whichever comes first.;   Overall Survival measured in month from the date of randomization to the date of death.;   Time to tumor progression measured in months from the date of randomization to the date of the first documented disease progression.;   overall response rate (i.e., the total of complete responses and partial responses to the study drug);
10 Unknown  Boron Neutron Capture Therapy (BNCT) for Locally Recurrent Head and Neck Cancer
Condition: Head and Neck Cancer
Intervention: Radiation: Boron Neutron Capture Therapy
Outcome Measures: Treatment toxicities and response rate;   Time to tumor progression;   Progression-free survival;   overall survival;   Change of quality of life
11 Recruiting BNCT and IG-IMRT for Recurrent Head and Neck Cancer
Conditions: Head and Neck Cancer;   Recurrence
Intervention: Radiation: BNCT + IG-IMRT
Outcome Measures: treatment toxicities;   response rate;   Time to tumor progression;   Progression-free survival
12 Recruiting Combine TACE and RFA Versus RFA Monotherapy in Unilobar HCC of 3.1 to 7 cm Patient
Condition: Hepatocellular Carcinoma
Interventions: Procedure: Transcatheter Arterial Chemoembolization;   Procedure: Radiofrequency ablation;   Drug: Doxorubicin
Outcome Measures: The rate of complete necrosis (CN);   Primary technique effectiveness;   local tumor progression of HCC;   Survival;   Major complication
13 Recruiting Predicting Risk of Cancer in Barrett's Esophagus
Conditions: Barrett Esophagus;   Esophageal Neoplasm;   Gastroesophageal Reflux
Intervention:
Outcome Measure: early predictors of esophageal cancer
14 Recruiting Sodium Selenite as a Cytotoxic Agent in Advanced Carcinoma
Conditions: Malignant Tumor;   Treatment Resistant Disorders;   Tumor Progression
Interventions: Drug: Sodium selenite (Introselen);   Drug: Sodium selenite
Outcome Measures: Maximal tolerable dose (phase I, ongoing);   Responses
15 Recruiting Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy
Conditions: Adenocarcinoma of the Prostate;   Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
Interventions: Drug: enzalutamide;   Other: laboratory biomarker analysis
Outcome Measures: Percent PSA change;   Progression-free survival;   Disease-specific survival;   Overall survival;   Time to PSA progression;   Molecular features and cellular pathways present in tumors that are progressing despite treatment with enzalutamide;   Objective response defined using the new international criteria proposed by the RECIST version 1.1;   Degree of PSA decline;   Maximal PSA decline observed
16 Recruiting Diet and Physical Activity Change or Usual Care in Improving Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Conditions: Brenner Tumor;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Undifferentiated Adenocarcinoma;   Stage IIA Fallopian Tube Cancer;   Stage IIA Ovarian Epithelial Cancer;   Stage IIA Primary Peritoneal Cavity Cancer;   Stage IIB Fallopian Tube Cancer;   Stage IIB Ovarian Epithelial Cancer;   Stage IIB Primary Peritoneal Cavity Cancer;   Stage IIC Fallopian Tube Cancer;   Stage IIC Ovarian Epithelial Cancer;   Stage IIC Primary Peritoneal Cavity Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Primary Peritoneal Cavity Cancer;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Primary Peritoneal Cavity Cancer;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Primary Peritoneal Cavity Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Primary Peritoneal Cavity Cancer
Interventions: Behavioral: behavioral dietary intervention;   Behavioral: exercise intervention;   Other: counseling intervention;   Other: educational intervention;   Behavioral: compliance monitoring;   Other: questionnaire administration;   Other: quality-of-life assessment;   Other: laboratory biomarker analysis
Outcome Measures: Progression-free survival;   Change in self-reported quality of life measured using RAND-36;   Change in irritable bowel syndrome-specific symptoms measured using GSRS-IBS
17 Recruiting Rapid Ligating the Corresponding Inflow and Outflow Vessels Without Hilus Dissection During Hepatectomy
Condition: Cancer Progression
Interventions: Procedure: hepatectomy (conventional method);   Procedure: hepatectomy (rapid ligating)
Outcome Measures: recurrence;   metastasis;   mortality;   Prognosis
18 Recruiting Erlotinib With Concurrent Brain Radiotherapy and Secondary Brain Radiotherapy After Recurrence With Erlotinib in NSCLC Non-increased-intracranial-pressure Symptomatic Brain Metastases
Conditions: Non-small-cell Lung Cancer;   Brain Metastases
Interventions: Drug: Erlotinib;   Radiation: concurrent brain radiotherapy;   Radiation: secondary brain radiotherapy
Outcome Measure: overall survival
19 Recruiting Biomarkers in Tissue Samples From Patients With Newly Diagnosed Breast Cancer Treated With Zoledronic Acid
Conditions: Estrogen Receptor-positive Breast Cancer;   Invasive Ductal Breast Carcinoma;   Progesterone Receptor-positive Breast Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer
Interventions: Drug: zoledronic acid;   Other: laboratory biomarker analysis;   Procedure: therapeutic conventional surgery
Outcome Measures: Changes in biomarkers of tumor growth and metastasis in women with newly diagnosed ER and/or PR positive invasive ductal breast cancer receiving zoledronic acid;   Changes in immunologic function after a single dose of zoledronic acid;   Changes in the expression of tumor markers important to breast cancer progression and metastasis in women receiving zoledronic acid
20 Recruiting Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Biological: Elotuzumab;   Drug: Bortezomib;   Drug: Dexamethasone
Outcome Measures: Progression-free survival (PFS) - Time from randomization to date of first tumor progression or death due to any cause;   PFS hazard ration in the subgroup of subjects with at least one FcγRIIIa V allele;   Difference in response rates between treatment arms in the overall population;   Estimate the difference in response rates between arms in the subgroup of subjects with at least one FcγRIIIa V allele

These studies may lead to new treatments and are adding insight into Sandostatin Lar Sas02 vial etiology and treatment.

A major focus of Sandostatin Lar Sas02 vial research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Sandostatin Lar Sas02 vial